Paxman AB (publ) announced that it has signed a letter of interest with a plan to enter in to a distribution and marketing agreement with Guangzhou Concord Medical Sci-Tech Innovation Center Co. Ltd. to jointly develop the market for the Paxman Scalp Cooling System within the Greater China territory, including Macau, Taiwan and Mongolia. The initial collaboration is for a period of five years and will include an evaluation period of 24 months to treat up to 300 patients at Concord Medical's Guangzhou Concord Cancer Center (GCCC), a National Health Commission certified tertiary specialty hospital, situated in Sino-Singapore Guangzhou Knowledge City.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.8 SEK | -4.53% | +3.77% | -2.72% |
Jan. 15 | Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.72% | 65.24M | |
-3.52% | 186B | |
-2.72% | 107B | |
-3.94% | 67.44B | |
+3.16% | 50.03B | |
+16.06% | 47.81B | |
+4.79% | 41.03B | |
+1.41% | 26.85B | |
+2.77% | 25.82B | |
-0.46% | 25.01B |
- Stock Market
- Equities
- PAX Stock
- News Paxman AB
- Paxman AB Signs Letter of Interest with Guangzhou Concord Medical Sci-Tech Innovation Center Co. Ltd. to Enter into Distribution and Marketing Agreement